Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.

Next Previous
Trial Profile

A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulocuplumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 31 Oct 2019 Results assessing safety and tolerability of ulocuplumab alone and in combination with lenalidomide and dexamethasone were published in the Clinical Cancer Research
  • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top